Get the Daily Brief
Latest Biotech News
Abbott to buy Exact Sciences for $23 billion — big med‑tech enters oncology testing
Abbott Laboratories agreed to acquire Exact Sciences for approximately $23 billion, a deal Abbott said will double its diagnostics addressable market by adding oncology screening,...
Cellarity’s AI flags drug‑induced liver injury — new toxicogenomics tool
Cellarity published an AI-driven toxicogenomics platform, ToxPredictor, supported by a DILImap transcriptomics library profiling 300 compounds, to predict dose-related drug-induced liver injury...
Tempus picks up OneOme pharmacogenetics assets — PGx market consolidates
Tempus acquired the pharmacogenetics assets of OneOme after the latter ceased operations, obtaining OneOme’s RightMed PGx test and related partnerships with health systems. Tempus said the deal...
Lawmakers press FDA on ultra‑fast review vouchers — transparency at issue
House Rep. Frank Pallone Jr. and Sen. Bernie Sanders sent a letter to FDA Commissioner Marty Makary expressing 'deep concerns' about the Commissioner's National Priority Voucher (CNPV) program,...
Semaglutide fails in Alzheimer’s... Two Phase III trials show no benefit
Novo Nordisk reported that two large Phase III trials testing oral semaglutide in early Alzheimer’s disease did not slow clinical decline, according to company statements and regulatory...
Novo accelerates amycretin pivots – Pivotal diabetes trials launched after Phase 2 win
Novo Nordisk is expanding development of amycretin, an amylin–GLP-1 combination, after Phase II data showed substantial reductions in body weight and blood glucose in patients with diabetes. The...
Bayer’s asundexian hits Phase III stroke goal – FXIa class revived
Bayer reported that asundexian, an oral factor XIa inhibitor, met its primary endpoint in a Phase III study, reducing recurrent ischemic stroke without increasing major bleeding, the company said...
Abbott to buy Exact Sciences: $23 billion deal reshapes diagnostics
Abbott Laboratories agreed to acquire Exact Sciences for $23 billion, combining Abbott’s diagnostics portfolio with Exact Sciences’ colorectal cancer screening, multi-cancer early detection, and...
AstraZeneca pledges $2 billion to Maryland – Biomanufacturing onshored, jobs promised
AstraZeneca announced a $2 billion investment to expand its biologics manufacturing footprint in Maryland, including a major expansion in Frederick and a new clinical-supply facility in...
Gilead buys TREX1 cancer program – $14M up front, $400M in biobucks
Gilead Sciences struck a deal to acquire a preclinical TREX1-targeting oncology program from Sprint Bioscience, paying $14 million upfront with potential milestone payments up to $400 million,...
NervGen posts durable gains in spinal cord injury – Expanded CONNECT data released
NervGen Pharma released expanded CONNECT SCI study data showing durable functional improvements in chronic spinal cord injury patients treated with NVG-291. The company reported gains that...
Lawmakers press FDA on new priority voucher scheme – Transparency, corruption flagged
Two congressional figures, Rep. Frank Pallone Jr. and Sen. Bernie Sanders, sent a letter to FDA Commissioner Marty Makary raising 'deep concerns' about the agency’s new Commissioner’s National...
FDA probes Takeda’s Adzynma after pediatric death – Neutralizing antibodies under review
The U.S. Food and Drug Administration is investigating reports that patients treated with Takeda’s Adzynma developed neutralizing antibodies, and that a pediatric patient’s death 'appears to be...
Pharmacogenetics consolidation: Tempus buys OneOme assets; Ovation and PrecisionLife to build GLP‑1 PGx test
Tempus has acquired the pharmacogenetics (PGx) assets of troubled OneOme, adding RightMed PGx capabilities and commercial partnerships to its diagnostics portfolio, GenomeWeb reported. Tempus said...
AstraZeneca doubles US biologics footprint: $2 billion Maryland build-out
AstraZeneca announced a $2 billion investment to expand biologics manufacturing in Maryland, enlarging its Frederick biologics plant and building a new clinical production site in Gaithersburg....
FDA clears Novartis’ Itvisma: gene therapy widened to older SMA patients
Novartis secured FDA approval for an expanded formulation of its one‑time gene therapy Itvisma aimed at older patients with spinal muscular atrophy (SMA). The approval extends the eligible patient...
Bayer’s FXIa drug snags Phase 3 stroke win – class revived
Bayer reported that its oral factor XIa inhibitor asundexian met the primary endpoint in a Phase 3 trial, reducing recurrent ischemic stroke without increasing major bleeding. The Oceanic Stroke...
Novo’s GLP‑1 Alzheimer hope fails... major Phase 3 misses
Novo Nordisk reported negative top‑line results from two large Phase 3 trials of oral semaglutide in early Alzheimer’s disease: the drug failed to slow cognitive and functional decline versus...
Abbott jumps into cancer testing: $23 billion Exact Sciences buy
Abbott Laboratories agreed to acquire Exact Sciences for $23 billion, a move that immediately expands Abbott’s diagnostics footprint into oncology screening, therapy selection and minimal residual...
NervGen posts durable gains in chronic spinal cord injury – expanded CONNECT data
NervGen released expanded CONNECT SCI data showing durable functional improvements and quality‑of‑life gains in individuals with chronic spinal cord injury treated with NVG‑291. The company...